Renibus Announces First Patient Enrolled in PROTECT Phase 3 Study of RBT-1 to Reduce Post-Operative Complications After Cardiothoracic Surgery

Renibus Therapeutics, a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal and metabolic diseases, announced that the first patient has been dosed in the pivotal Phase 3 PROTECT trial of RBT-1, the Company's first-in-a-new-class preconditioning agent under investigation to reduce post-operative complications following cardiothoracic surgery. PROTECT is expected to be conducted at approximately 35 sites in the United States and Canada.